Develops drugs for rare neurodegenerative diseases.
Jun 2026Revenue $136M/yrExpenses $53.7M/yr
No trend
Figures by year
Is Zevra Therapeutics profitable?
Yes. In the 12 months to Jun 2026, revenue was $136M and expenses $53.7M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $106M | $169M | −$62.9M |
| Dec 2024 | $23.6M | $111M | −$87.0M |
| Dec 2023 | $27.5M | $77.1M | −$49.6M |
| Dec 2022 | $10.2M | $52.7M | −$42.6M |
| Dec 2021 | $28.6M | $20.9M | $7.73M |
| Dec 2020 | $13.3M | $18.9M | −$5.61M |
| Dec 2019 | $12.8M | $33.2M | −$20.3M |
| Dec 2018 | $0.00 | $55.9M | −$55.9M |
| Dec 2015 | $0.00 | $22.8M | −$22.8M |
| Dec 2014 | $0.00 | $16.4M | −$16.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.